The objective of this webinar, presented by the International AIDS Society is to provide the latest updates on long-acting injectable PrEP, including science and research emerging from recent conferences. Participants will also hear the civil society perspective on the evolving PrEP landscape, as well as on-the-ground approaches to increase access to long-acting PrEP.
Moderator: Renata Sanders, Associate Professor of Paediatrics, Johns Hopkins University School of Medicine, and IAS Governing Council Member
Confirmed speakers so far include:
- Sunil Solomon, Associate Professor of Medicine, Johns Hopkins University School of Medicine
- Shakirah Namwanje, Programs Officer, UNASO, Uganda, and Member of African Women Community Prevention Accountability Board
- Mitchell Warren, Executive Director, AVAC, and IAS Governing Council Member
The Lancet HIV- Special Issue on PrEP
The December 2023 issue of The Lancet HIV contains numerous articles featuring the latest research and commentaries on PrEP, including oral PrEP, injectable CAB for PrEP, the dapirivine vaginal ring, and PEP.
What can modelling tell us about the scale-up of CAB for PrEP?
This factsheet summarises the results of mathematical modelling exercises of Cabotegravir (CAB) for PrEP rollout undertaken by researchers affiliated with the HIV Modelling Consortium. These results can help implementers and policymakers understand what to expect and guide early policy decisions to ensure CAB for PrEP is able to have maximum impact on reducing the HIV…
Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)
The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…
Quality Improvement Brief
The Quality Improvement Collaborative (QIC) is a component of the CATALYST study that refines and makes context-specific improvements to the enhanced service delivery package to make it scalable for delivering PrEP choice. The QIC’s multi-country design enables rich learning and problem-solving by providing QI faculty, advisors, coaches, and teams from all CATALYST countries opportunities to…
Insights Report: Communicating the PrEP Category to AGYW
PrEP Category Positioning Market Research Validation Insights from Kenya, South Africa, and Zimbabwe This report is a comprehensive look at what was learned through validating the positioning direction. It explains the methodology, outlines country-specific reactions to the positioning direction, and distills key findings that were leveraged to adjust and refine the positioning to honor the…
Communicating the PrEP Category to Adolescent Girls and Young Women
This strategy brief is intended for use by implementers working to generate demand for PrEP among AGYW. Drawing on all learnings throughout the positioning process, the brief provides a narrative explanation of how to communicate the PrEP category to AGYW and includes actionable guidance on how best to develop communication that will get the attention…
PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia: The PrEP APPEAL Study
This report provides an overview of PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia (PrEP APPEAL), a survey study in 16 countries and territories in Asia and Australia. The overall goal of PrEP APPEAL was to identify values and preferences about PrEP,…
Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…
Advocates’ Primer on Injectable Cabotegravir for PrEP
This document, designed for advocates, focuses on injectable cabotegravir for PrEP, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy. A summary slide deck with additional details can be found here.